Friday, 21 August 2015 12:46

20th International Vicenza Course on Hemodialysis and CKD

By  Vicenza
Rate this item
(0 votes)

vicenza course

 

20th International Vicenza Course on Hemodialysis and CKD

Opening Ceremony

  • Opening Remarks - C. Ronco
  • Welcome from Italian Society of Nephrology - R. Coppo
  • International Society for Hemodialysis award for best abstracts -M. Misra
  • Invited Opening Lecture: The future of health care reform - A.Milburn

Session 1: Organization Models: Dialysis Networks 

  • The Search for a Standard of Care - J.Hegbrant
  • Risk Management: working for safety - J.Bosch
  • The Medical Director: working efficacy - A. Nissenson
  • Delivering optimal quality of care managing all stakeholders' interests - A.Stopper

Session 2: New Perspectives in HD

  • HD initiation in relationship to the IDEAL data - J.Collins
  • Lessons from recent trials in HD - S.Locatelli
  • More frequent hemodialysis; what do we know, where do we stand? - N. Levin
  • Nocturnal Dialysis: the FHN trial - M. Rocco
  • Dialysis management in elderly patients - M. Rosner
  • Perspectives in home HD therapy - N. Hoenich

Session 3: Cardiovascular Issues

  • Uric acid: metabolic and cardiovascular risk - A. Covic
  • Micro inflammation and endothelial damage in CKD and hemodialysis - P. Aljama
  • Biomarkers of chronic inflammatory state in uremia and CVD - V. Panichi
  • The burdne of cardiovascular risk in CKD and dialysis patients (CRS Type 4) - A.House
  • Disparities of treatment for ACS and Heart Failure in CKD patients - P. Mc Cullough

Session 4: Vascular access and dry weight

  • Is Dialysis Catheter harming the patient? - M. Kuhlmann
  • The evils of intradialytic sodium loading - P. Kotanko
  • Is AV fistula harming the patient? - R. Amerling
  • The concept of wet and dry BNP - A. Maisel
  • The wonders of ultrasonography - M. Pittiruti

Session 5: Evolution of Dialysis Membranes

  • Recent trials on Hemodiafiltration - F.Locatelli
  • The treatment of HCV with Affinity Plasmapheresis on Dialysis Machines - R. Kenley
  • From High flux to super high flux - M. Kuhlmann
  • Antioxidant dialytic approach with vitamin E coated membranes - F. Nalesso
  • Light chain removal: HCO membranes - A. Santoro

Session 6: Lipid disorders & metabolism

  • Statins and lipid lowering strategies in cardio-renal patients - S.Bianchi
  • Results from recent trials - D. de Zeeuw
  • Factors determining insulin resistance in hemodialysis patients - A. Ikizler
  • The spectrum of metabolic alterations in dialysis - M. Misra
  • Lipid disorders in uremia and dialysis - W.Keane
  • New insights on inflammation and protein energy wasting in CKD - P.Stenvinkel

Session 7: Ca, P, Vit D and VDRA 

  • VDR Activators: clinical outcomes - A. Covic
  • Restoring the physiology of VDR activation and the concept of selectivity - M. Cozzolino
  • The impact of paricalcitol on CKD progression measured by albuminuria (The VITAL study) - D. de Zeeuw
  • The impact of paricalcitol on LVH (The PRIMO study) - M. Cozzolino
  • VDRA: Implications to daily practice - D. Warnock

Session 8: Fluid overload in HD and AKI

  • Blood Volume & Biofeedback - A.Santoro
  • Body composition and Heart rate variability to achieve dry weight and tolerance - F. Nalesso
  • Extracorporeal Ultrafiltration for congestive heart failure patients - M.R. Costanzo
  • BIVA + BNP in the emergency room - S. Di Somma

Session 9: Acute Kidney Injury

  • AKI Biomarkers and endpoints for Clinical Trials - P. Murray
  • AKI: can we prevent it? - P. Mc Cullough
  • Impact of AKI on CKD and its progression - M.Okusa
  • Special Lecture: Acute Kidney Injury and its management - J. Kellum

Session 10: Wearable Dialysis Technology

  • Financial implications from application of wearable technology - R. Greenwood
  • Clinical benefits of a wearable approach - A. Davenport
  • The WAK project: where are we? - V. Gura
  • Wearable dialysis: what is missing - H.D. Polaschegg
  • Wearable ultrafiltration for heart failure - C. Ronco

Session 11: Anemia and its management

  • New ESAs and new Iron formulations - F. Locatelli
  • Impact of dialytic technique on anemia - V. Panichi
  • Anemia Trials in CKD and Clinical practice: Refining the approach to ESA's use - A. De Francisco
  • Anemia and Hypoalbuminemia as Prognostic Indicators in HD: Fact or Artefact? - R. Amerling
  • Anemia in HD and PD: similar treatments? - J. Burkart
  • The Cardio Renal Anemia syndrome - S. von Heahling

Additional Info

  • Language: English
  • Contains Audio: Yes
  • Content Type: Presentations
  • Source: Other sources
  • Year: 2011
  • Members Only: No
Read 2289 times Last modified on Thursday, 04 August 2016 20:21

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact

               

Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact